Spots Global Cancer Trial Database for egfr activating mutation

Every month we try and update this database with for egfr activating mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations	NCT02949843	EGFR Activating... Recurrent Non-S... Stage IV Non-Sm...	Chemotherapy Immunotherapy Laboratory Biom... Nivolumab Pembrolizumab Targeted Molecu... Tyrosine Kinase...	-	Wake Forest University Health Sciences
A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC	NCT04636593	Non Small Cell ... Stage III NSCLC EGFR Activating...	Almonertinib	18 Years -	First People's Hospital of Hangzhou
Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation	NCT04233021	Non Small Cell ... Leptomeningeal ... Brain Metastase... EGFR Activating...	Osimertinib	18 Years -	Intergroupe Francophone de Cancerologie Thoracique
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations	NCT05258279	Non-squamous No... EGFR Activating...	Pembrolizumab Lenvatinib Carboplatin Pemetrexed	20 Years -	Juntendo University
Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation	NCT05778149	Aumolertinib Anlotinib TP53 NSCLC EGFR Activating...	Aumolertinib,An...	18 Years - 75 Years	Tianjin Medical University Cancer Institute and Hospital
CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease	NCT05257967	EGFR Activating... Leptomeningeal ... Non Small Cell ...	Lumbar puncture...	18 Years -	British Columbia Cancer Agency
Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC	NCT02299765	Non-small Cell ... EGFR Activating...	Gefitinib gemcitabine carboplatin	18 Years - 75 Years	Sichuan University
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC	NCT04989322	Nsclc EGFR Activating... EGF-R Positive ... ALK Gene Rearra... ROS1 Gene Rearr... ROS1 Positive N...	Pembrolizumab Lenvatinib Pemetrexed Carboplatin	18 Years -	The University of Hong Kong
Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis	NCT04148898	Leptomeningeal ... Non-small Cell ... EGFR Activating...	Osimertinib Bevacizumab	18 Years - 80 Years	Second Affiliated Hospital of Nanchang University
Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation	NCT05778149	Aumolertinib Anlotinib TP53 NSCLC EGFR Activating...	Aumolertinib,An...	18 Years - 75 Years	Tianjin Medical University Cancer Institute and Hospital
Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC	NCT05244213	Non-small Cell ... EGFR Activating...	Sintilimab Carboplatin Nab paclitaxel	18 Years - 75 Years	Guangdong Provincial People's Hospital
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases	NCT05948813	NSCLC EGFR Activating... Brain Metastase...	TY-9591 Osimertinib	18 Years - 80 Years	TYK Medicines, Inc
Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors	NCT03647956	NSCLC Stage III... NSCLC Stage IV EGFR Activating...	Atezolizumab Bevacizumab Carboplatin Pemetrexed	18 Years -	The University of Hong Kong
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)	NCT05382728	NSCLC EGFR Activating...	TY-9591 placebo Osimert... Osimertinib placebo TY-9591	18 Years - 80 Years	TYK Medicines, Inc
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC	NCT04989322	Nsclc EGFR Activating... EGF-R Positive ... ALK Gene Rearra... ROS1 Gene Rearr... ROS1 Positive N...	Pembrolizumab Lenvatinib Pemetrexed Carboplatin	18 Years -	The University of Hong Kong
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	NCT04862780	Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR T790M EGFR C797S EGFR L858R EGFR Gene Mutat... EGF-R Positive ... EGFR Exon 19 De... EGFR Mutation R... EGFR Activating... Protein Kinase ... Antineoplastic ... Thoracic Neopla...	BLU-945 osimertinib	18 Years -	Blueprint Medicines Corporation
Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases	NCT05768490	Brain Metastase... Radiotherapy EGFR Activating...	brain radiother... Almonertinib	18 Years - 75 Years	Sun Yat-sen University
Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer	NCT02846792	ALK Gene Transl... EGFR Activating... Recurrent Non-S... ROS1 Gene Trans... Stage IIIB Non-... Stage IV Non-Sm...	Nivolumab Plinabulin	18 Years -	University of Washington
A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)	NCT06053099	Non Small Cell ... EGFR Activating... EGFR DEL19 EGFR L858R	Plasma ctDNA FFPE blocks	18 Years -	Intergroupe Francophone de Cancerologie Thoracique
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC	NCT05153408	Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR C797S EGFR C797A EGFR L858R EGFR Exon 19 De... EGFR Gene Mutat... EGF-R Positive ... EGFR Mutation R... EGFR Activating... Thoracic Neopla... Antineoplastic ... Protein Kinase ... EGFR C797G EGFR C797X Non Small Cell ...	BLU-701 osimertinib carboplatin pemetrexed	18 Years -	Blueprint Medicines Corporation
Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations	NCT02949843	EGFR Activating... Recurrent Non-S... Stage IV Non-Sm...	Chemotherapy Immunotherapy Laboratory Biom... Nivolumab Pembrolizumab Targeted Molecu... Tyrosine Kinase...	-	Wake Forest University Health Sciences
Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis	NCT04944069	NSCLC Leptomeningeal ... EGFR Activating...	Almonertinib Bevacizumab	18 Years - 75 Years	Second Affiliated Hospital of Nanchang University
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations	NCT05258279	Non-squamous No... EGFR Activating...	Pembrolizumab Lenvatinib Carboplatin Pemetrexed	20 Years -	Juntendo University
TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC	NCT03916913	Non-Small Cell ...	Local radiation...	18 Years - 75 Years	ChineseAMS
Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer	NCT04425681	Leptomeningeal ... Non-small Cell ... EGFR Activating...	Osimertinib Bevacizumab	18 Years - 80 Years	Second Affiliated Hospital of Nanchang University
Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation	NCT05146219	NSCLC EGFR Activating... Brain Metastase... Leptomeningeal ...	TY-9591 Tablets	18 Years -	TYK Medicines, Inc
Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation	NCT05146219	NSCLC EGFR Activating... Brain Metastase... Leptomeningeal ...	TY-9591 Tablets	18 Years -	TYK Medicines, Inc
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations	NCT05241873	Lung Neoplasm M... Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... EGFR Exon 20 Mu... EGFR Exon 20 In... EGFR Activating... Antineoplastic ... Metastatic Lung... Brain Metastase... EGFR-mutated NS... EGFR Atypical M...	BLU-451 Carboplatin Pemetrexed	18 Years -	Blueprint Medicines Corporation
A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI	NCT03050437	Carcinoma, Non-...	Cisplatin Pemetrexed	20 Years -	Samsung Medical Center
Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC	NCT05244213	Non-small Cell ... EGFR Activating...	Sintilimab Carboplatin Nab paclitaxel	18 Years - 75 Years	Guangdong Provincial People's Hospital
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	NCT04862780	Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR T790M EGFR C797S EGFR L858R EGFR Gene Mutat... EGF-R Positive ... EGFR Exon 19 De... EGFR Mutation R... EGFR Activating... Protein Kinase ... Antineoplastic ... Thoracic Neopla...	BLU-945 osimertinib	18 Years -	Blueprint Medicines Corporation
Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer	NCT02846792	ALK Gene Transl... EGFR Activating... Recurrent Non-S... ROS1 Gene Trans... Stage IIIB Non-... Stage IV Non-Sm...	Nivolumab Plinabulin	18 Years -	University of Washington
Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases	NCT05768490	Brain Metastase... Radiotherapy EGFR Activating...	brain radiother... Almonertinib	18 Years - 75 Years	Sun Yat-sen University
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)	NCT05382728	NSCLC EGFR Activating...	TY-9591 placebo Osimert... Osimertinib placebo TY-9591	18 Years - 80 Years	TYK Medicines, Inc
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases	NCT05948813	NSCLC EGFR Activating... Brain Metastase...	TY-9591 Osimertinib	18 Years - 80 Years	TYK Medicines, Inc
A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC	NCT04636593	Non Small Cell ... Stage III NSCLC EGFR Activating...	Almonertinib	18 Years -	First People's Hospital of Hangzhou
CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease	NCT05257967	EGFR Activating... Leptomeningeal ... Non Small Cell ...	Lumbar puncture...	18 Years -	British Columbia Cancer Agency
Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC	NCT04768491	EGFR Activating... NSCLC Stage IV NSCLC Stage III... NSCLC, Recurren...	Dacomitinib	18 Years -	Peking Union Medical College

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: